GPT-Rosalind
Open in the interactive archive →
Overview
Frontier reasoning model purpose-built for life sciences, biology, drug discovery, and translational medicine. Optimized for chemistry, protein engineering, and genomics workflows with enhanced tool use.
Details
- Vendor
- OpenAI
- Type
- Science/Biology
- Release year
- 2026
- Jurisdiction
- USA
- CEO
- Sam Altman
- Key staffers
- Greg Brockman (President), Jakub Pachocki (Chief Scientist), Brad Lightcap (COO), Fidji Simo (CEO Applications), Sarah Friar (CFO), Mark Chen (SVP Research), Denise Dresser (CRO)
- Deployment
- Cloud only (proprietary, limited access)
- Open source
- No
- Free tier
- No
- Subscription
- Limited access via request; enterprise research partnerships
- Stock status
- Private (~$852B valuation, Mar 2026)
- X
- @OpenAI
Capabilities
Pdf GenerationSpreadsheet Generation
AIDb Rating
AIDb v2.0 (curated): Capability 8.5/10 · Currency 9/10 · Access 2/10 · Significance 7/10 → 7.40
Safety notes
Limited-access release for vetted researchers; dual-use biology risk reviewed through OpenAI Preparedness Framework.
Last verified 2026-06-11 · Primary source ↗
Cite this
“GPT-Rosalind.” AIDb — The AI Database. Verified 2026-06-11. https://theaidatabase.com/m/openai-gpt-rosalind.html
More from OpenAI
ChatGPT · ChatGPT Canvas · CLIP · CLIP (ViT B/32) · CLIP (ViT L/14) · Codex (original)